185 related articles for article (PubMed ID: 28411920)
1. Neoadjuvant Targeted Molecular Therapy Before Renal Surgery.
Dey S; Peabody HN; Noyes SL; Lane BR
Urol Clin North Am; 2017 May; 44(2):289-303. PubMed ID: 28411920
[TBL] [Abstract][Full Text] [Related]
2. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
Thomas AA; Rini BI; Lane BR; Garcia J; Dreicer R; Klein EA; Novick AC; Campbell SC
J Urol; 2009 Feb; 181(2):518-23; discussion 523. PubMed ID: 19100579
[TBL] [Abstract][Full Text] [Related]
3. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.
Cost NG; Delacroix SE; Sleeper JP; Smith PJ; Youssef RF; Chapin BF; Karam JA; Culp S; Abel EJ; Brugarolas J; Raj GV; Sagalowsky AI; Wood CG; Margulis V
Eur Urol; 2011 Jun; 59(6):912-8. PubMed ID: 21367518
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.
Rini BI; Plimack ER; Takagi T; Elson P; Wood LS; Dreicer R; Gilligan T; Garcia J; Zhang Z; Kaouk J; Krishnamurthi V; Stephenson AJ; Fergany A; Klein EA; Uzzo RG; Chen DY; Campbell SC
J Urol; 2015 Aug; 194(2):297-303. PubMed ID: 25813447
[TBL] [Abstract][Full Text] [Related]
5. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant and adjuvant treatment of renal cell carcinoma.
Thillai K; Allan S; Powles T; Rudman S; Chowdhury S
Expert Rev Anticancer Ther; 2012 Jun; 12(6):765-76. PubMed ID: 22716493
[TBL] [Abstract][Full Text] [Related]
7. Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
Kwon T; Lee JL; You D; Jeong IG; Song C; Ahn H; Kim CS; Hong JH
J Surg Oncol; 2014 Aug; 110(2):145-50. PubMed ID: 24706355
[TBL] [Abstract][Full Text] [Related]
8. Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy.
Tilki D; Hu B; Nguyen HG; Dall'Era MA; Bertini R; Carballido JA; Chandrasekar T; Chromecki T; Ciancio G; Daneshmand S; Gontero P; Gonzalez J; Haferkamp A; Hohenfellner M; Huang WC; Koppie TM; Linares E; Lorentz CA; Mandel P; Martinez-Salamanca JI; Master VA; Matloob R; McKiernan JM; Mlynarczyk CM; Montorsi F; Novara G; Pahernik S; Palou J; Pruthi RS; Ramaswamy K; Rodriguez Faba O; Russo P; Shariat SF; Spahn M; Terrone C; Thieu W; Vergho D; Wallen EM; Xylinas E; Zigeuner R; Libertino JA; Evans CP
J Urol; 2015 Feb; 193(2):436-42. PubMed ID: 25063493
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?
Schrader AJ; Steffens S; Schnoeller TJ; Schrader M; Kuczyk MA
Int J Urol; 2012 Oct; 19(10):903-7. PubMed ID: 22640774
[TBL] [Abstract][Full Text] [Related]
10. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
[TBL] [Abstract][Full Text] [Related]
11. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial.
Karam JA; Devine CE; Fellman BM; Urbauer DL; Abel EJ; Allaf ME; Bex A; Lane BR; Thompson RH; Wood CG
BJU Int; 2016 Apr; 117(4):629-35. PubMed ID: 26033220
[TBL] [Abstract][Full Text] [Related]
12. Oncological outcomes in patients undergoing radical nephrectomy and vena cava thrombectomy for renal cell carcinoma with venous extension: a single-centre experience.
Parra J; Drouin SJ; Hupertan V; Comperat E; Bitker MO; Rouprêt M
Eur J Surg Oncol; 2011 May; 37(5):422-8. PubMed ID: 21330093
[TBL] [Abstract][Full Text] [Related]
13. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.
Bex A; Powles T
Expert Rev Anticancer Ther; 2012 Jun; 12(6):787-97. PubMed ID: 22716495
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
McKiernan J; Wood CG
J Urol; 2013 Aug; 190(2):386-8. PubMed ID: 23702308
[No Abstract] [Full Text] [Related]
16. [Neoadjuvant targeted therapies in renal cell carcinoma].
Bigot P; Pignot G; Bernhard JC; Patard JJ
Prog Urol; 2016 Mar; 26(3):191-6. PubMed ID: 26781767
[TBL] [Abstract][Full Text] [Related]
17. Sequential immune-targeted surgical therapy resulted in disease-free survival in a case with advanced renal cell carcinoma.
Nishimura K; Miura N; Sugihara N; Funaki K; Koyama K; Sawada Y; Noda T; Fukumoto T; Miyauchi Y; Kikugawa T; Saika T; Matsumura M; Hashine K; Taniwaki M
BMC Urol; 2021 Sep; 21(1):124. PubMed ID: 34496819
[TBL] [Abstract][Full Text] [Related]
18. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy.
Spiess PE; Kurian T; Lin HY; Rawal B; Kim T; Sexton WJ; Pow-Sang JM
BJU Int; 2012 Dec; 110(11 Pt B):E470-4. PubMed ID: 22519938
[TBL] [Abstract][Full Text] [Related]
19. Targeted caval cytoreduction: solid foundations or shifting sands?
Bex A; Clarke N
Eur Urol; 2011 Jun; 59(6):919-20; discussion 921-2. PubMed ID: 21444147
[No Abstract] [Full Text] [Related]
20. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy.
You D; Jeong IG; Ahn JH; Lee DH; Lee JL; Hong JH; Ahn H; Kim CS
J Urol; 2011 Jan; 185(1):54-9. PubMed ID: 21074811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
